Login to Your Account

Earnings Roundup

Friday, November 9, 2012
• InterMune Inc., of Brisbane, Calif., reported net revenue in the third quarter of $7.5 million from sales of Esbriet (pirfenidone) for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription